Published in final edited form as:

Bioorg Med Chem. 2009 July 15; 17(14): 5126–5132. doi:10.1016/j.bmc.2009.05.052.

Synthesis and structure-activity relationship of 3β-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3β-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters

Chunyang Jin^{*}, Hernán A. Navarro, and F. Ivy Carroll

Organic and Medicinal Chemistry, Research Triangle Institute, PO Box 12194, Research Triangle Park, NC 27709-2194, USA

Abstract

$R_1 = \text{CH}_3, \text{CF}_3, \text{C}_2\text{H}_5, \text{CH}(\text{CH}_3)_2$
 $R_2 = \text{H}, \text{CH}_3, \text{FCH}_2\text{CH}_2\text{CH}_2, \text{CH}_2=\text{CH}_2\text{CH}_2, \text{CH}_3\text{CH}_2\text{CH}_2$
 $X = \text{H}, \text{Br}$
 $n = 0, 1, 2$

Early studies led to the identification of 3β-(4-methoxyphenyl)tropane-2β-carboxylic acid methyl ester (**5**) with high affinity at the DAT ($\text{IC}_{50} = 6.5 \text{ nM}$) and 5-HTT ($K_i = 4.3 \text{ nM}$), while having much less affinity at the NET ($K_i = 1110 \text{ nM}$). In the present study, we replaced the 4'-methoxy group of the 3β-phenyl ring with a bioisosteric 4'-methylthio group to give **7a**. We also synthesized a number of 3β-(4-alkylthiophenyl)tropanes **7b-e**, 3β-(4-methylsulfinylphenyl) and 3β-(4-methylsulfonylphenyl)tropane analogues **7f-h** as well as the 3β-(4-alkylthiophenyl)nortropane derivatives **8-11** to further characterize the structure-activity relationship of this type of compound for binding at monoamine transporters. With exception of the 4'-methylsulfonyl analogue **7h**, all the tested compounds possessed high binding affinities at the 5-HTT. The K_i values ranged from 0.19 nM to 49 nM. The 3β-(4-methylthiophenyl)tropane **7a** and its *N*-(3-fluoropropyl) analogue **9a** and *N*-allyl analogue **10a** are the most selective compounds for the 5-HTT over the NET (NET/5-HTT = 314-364) in the series. However, none of the compounds showed selectivity similar to **5** for both the DAT and 5-HTT relative to the NET. This study provided useful SAR information for rational design of potent and selective monoamine transporter inhibitors.

© 2009 Elsevier Ltd. All rights reserved.

^{*}Corresponding author: Dr. Chunyang Jin Research Triangle Institute Post Office Box 12194 Research Triangle Park, NC 27709-2194 Telephone: 919 541-6328 Fax: 919 541-6499 cjin@rti.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Monoamine transporters; 3-Phenyltropanes; 3-Phenylnortropanes; Cocaine; Addiction

1. Introduction

Monoamine neurotransmitter transporters are the principle sites of action for cocaine (**1**, Fig. 1) and other stimulants.¹⁻⁵ Compounds with high affinity and selectivity for the dopamine, serotonin, and norepinephrine transporters (DAT, 5-HTT, and NET, respectively) are all of interest. In the brain, cocaine binds to the DAT, 5-HTT, and NET, and inhibits presynaptic reuptake of the respective neurotransmitters. It also has effects on the cholinergic, muscarinic, and σ receptors as well as sodium channels.⁶⁻⁹ The behavioural and reinforcing effects of cocaine result primarily from inhibition of the DAT and subsequent increases in extracellular levels of dopamine (DA), which in turn stimulate postsynaptic DA receptors.^{4, 7, 10-15} Hence, the discovery and development of potent and selective DAT inhibitors represents one of the promising approaches for the treatment of cocaine abuse. Several lines of evidence have suggested that inhibition of the 5-HTT can also modulate the reinforcing properties of cocaine.^{14, 16-18} Animal behaviour studies demonstrated that selective serotonin (5-HT) uptake inhibitors as well as dopamine uptake inhibitors can attenuate cocaine-induced stimulant and reinforcing effects.^{19, 20} Accordingly, the mixed action inhibitors of DAT and 5-HTT have received much attention as potential pharmacotherapies for treating cocaine abuse.²¹⁻²⁴

The exploration of potent and selective monoamine transporter inhibitors for cocaine abuse therapy depends on an understanding of the mechanisms of action and their structure-activity relationships (SAR). This has been accomplished experimentally by correlation of the structural variation with inhibition of [³H]WIN35,428, [³H]paroxetine, and [³H]nisoxetine binding at the DAT, 5-HTT, and NET, respectively.²⁵ The information was used as an indication of the compound's potential ability to inhibit uptake of the DA, 5-HT, and norepinephrine (NE) neurotransmitters. Over the last decade, we and others have synthesized a large number of 3-phenyltropane analogues with 3 β -phenyltropane-2 β -carboxylic acid methyl ester (WIN35,065-2, **2**) as the lead compound, and evaluated them for binding at monoamine transporters in order to identify the key structural features required for potent and selective monoamine transporter inhibitors.^{6, 25-34} Generally, the overall tropane configuration, the substituents and substitution pattern on the 3-aromatic ring, the nature of the 2 β -substituents, and the N-substitution are all important for the ligand recognition site interaction. One of the most studied compounds, the DAT selective inhibitor 3 β -(4-chlorophenyl)-2 β -[3-(4'-methylphenyl)isoxazol-5-yl]tropane (RTI-336, **6**) is currently in advanced preclinical development.³⁵⁻³⁷

In order to gain a better understanding of the molecular mechanisms of cocaine actions in the brain and find highly potent and selective monoamine uptake inhibitors, we have continued our SAR studies of **2**. In a recent study, we reported that 3 β -(4-methoxyphenyl)tropane-2 β -carboxylic acid methyl ester (**5**) possessed high affinity at the DAT (IC₅₀ = 6.5 nM) and 5-HTT (K_i = 4.3 nM), while having much less affinity at the NET (K_i = 1110 nM).²³ Thus, **5** is a promising lead compound to further develop ligands with high affinities for both the DAT and 5-HTT, and low affinity for the NET. In this study, we replaced the 4'-methoxy group of the 3 β -phenyl ring in **5** with the corresponding bioisosteric 4'-methylthio group and further characterized the SAR of this type of compound for binding at the DAT, 5-HTT, and NET. We report herein the synthesis and monoamine transporter binding properties of novel 3 β -(4-alkylthiophenyl)tropanes **7a-e**, 3 β -(4-methylsulfinylphenyl) and 3 β -(4-methylsulfonylphenyl) tropane analogues **7f-h**, and 3 β -(4-alkylthiophenyl)nortropane derivatives **8-11** (Fig. 2).

2. Chemistry

All the 3-phenyltropane compounds described herein were prepared starting from natural (—)-cocaine, and therefore, they are optically active and possess the same absolute configuration as (—)-cocaine. The synthesis of 3 β -(4-alkylthiophenyl)tropanes **7a-e**, and 3 β -(4-methylsulfinylphenyl) and 3 β -(4-methylsulfonylphenyl)tropane analogues **7f-h** is outlined in Schemes 1 and 2. Conjugate addition³⁸ of the appropriate Grignard reagent to anhydroecgonine methyl ester (**12**) at -45 °C in ethyl ether followed by the addition of trifluoroacetic acid (TFA) afforded **7a-c** in good yields ranging from 61% to 86% (Scheme 1). The addition of 4-trifluoromethylthiophenyl magnesium bromide to **12** gave only 7% yield (40% based on the recovered **12**) of **7d**. Bromination of 3 β -(4-methylthiophenyl)tropane-2 β -carboxylic acid methyl ester (**7a**) with 2 equivalents of bromine in acetic acid afforded the desired 3 β -(3-bromo-4-methylthiophenyl)tropane **7e** in 13% yield, as well as oxidation products 3 β -(3-bromo-4-methylsulfinylphenyl)tropane **7f** and 3 β -(4-methylsulfinylphenyl)tropane **7g** in 15% and 34% yields, respectively (Scheme 2). Use of 1 equivalent of bromine didn't improve the bromination reaction as judged by TLC analysis. Oxidation of **7a** using 30% hydrogen peroxide in acetic acid provided the sulfone analogue **7h** in 84% yield.

The synthesis of 3 β -(4-alkylthiophenyl)nortropane analogues **8-11** is presented in Scheme 3. Treatment of 3-phenyltropanes **7a,b** with 1-chloroethyl chloroformate afforded the corresponding (1-chloroethyl)urethane intermediates, which were converted to the *N*-nortropanes **8a,b** in 86% and 87% yields, respectively, by solvolysis with methanol.³⁹ *N*-Alkylation of **8a,b** with 1-bromo-3-fluoropropane using potassium carbonate in acetonitrile afforded *N*-(3-fluoropropyl)nortropane analogues **9a,b** in 94% and 87% yields, respectively. Using similar conditions, **8a,b** were alkylated with allyl bromide in the presence of catalytic potassium iodide to provide **10a,b** in 79% and 83% yields, respectively. Finally, the *N*-propylnortropanes **11a,b** were prepared in 60-88% yield by hydrogenation of the corresponding *N*-allyl analogues **10a,b** over 10% palladium on carbon. The ¹H NMR data of the target compounds are in agreement with the assigned structures. The chemical shift and coupling pattern of the C(2)-H and C(3)-H are consistent with previously reported compounds that possess the 2 β ,3 β -stereochemistry.⁴⁰⁻⁴²

3. Biology

Binding affinities at the DAT, 5-HTT, and NET represent inhibition of 0.5 nM [³H]WIN35,428, 0.2 nM [³H]paroxetine, and 0.5 nM [³H]nisoxetine binding, respectively, determined as previously reported.^{41,42} The results of the binding studies, along with binding data of cocaine and **5**²³ for comparison are listed in Tables 1 and 2. The DAT has two binding sites, and thus IC₅₀ values are reported. Since the 5-HTT and NET have only one binding site, K_i values were calculated for inhibition of binding at these two transporters.

4. Results and Discussion

SAR studies of the 3-phenyltropane class of monoamine uptake inhibitors from our laboratory, as well as from others, have addressed the key structural features required for binding to the DAT, as well as the 5-HTT and NET.^{25, 31, 43} The binding affinity and selectivity of compounds for the monoamine transporter is highly dependent on the nature and position of the substituents on the 3 β -phenyl ring.^{25, 31, 44} Recently, we reported that the 4'-methoxy analogue **5** is selective for both the DAT (IC₅₀ = 6.5 nM) and 5-HTT (K_i = 4.3 nM) relative to the NET (K_i = 1110 nM).²³ In this study, we replaced the 4'-methoxy group of **5** with the bioisosteric 4'-methylthio group to give 3 β -(4-methylthiophenyl)tropane-2 β -carboxylic acid methyl ester (**7a**). We also synthesized a number of 3 β -(4-alkylthiophenyl) analogues of **7a** and expanded the 3 β -(4-methylthiophenyl)tropane to the corresponding 3 β -(4-methylsulfinylphenyl) and 3 β -(4-

methylsulfonyl-phenyl)tropanes as well as 3 β -(4-alkylthiophenyl)nortropanes with variants of the N-substituents to further characterize the SAR of this type of compound. The ratio of K_i /IC₅₀ values of NET/DAT and the ratio of K_i values of NET/5-HTT were calculated as a measure of the in vitro selectivity of the compounds for the DAT relative to the NET and the 5-HTT relative to the NET, respectively. As shown in Table 1, replacement of the 4'-methoxy group of **5** with the 4'-methylthio group afforded **7a** with a comparable DAT affinity as that of **5** (9 nM vs. 6.5 nM) and enhanced affinities for both the 5-HTT and NET. The magnitude of increase at the 5-HTT is more than that of the NET, leading to increased selectivity for the 5-HTT relative to the NET (NET/5-HTT ratio of 314 of **7a** vs. 258 of **5**). Thus, **7a** is more potent at the 5-HTT and more selective for the 5-HTT over the NET than **5**. Changing the 4'-methylthio group of **7a** with a slightly larger 4'-ethylthio group resulted in **7b**, which had less potency for all three monoamine transporters, with the biggest loss of affinity at the DAT (232 nM vs. 9 nM of **7a**). Somewhat surprisingly, the 4'-isopropylthio analogue **7c** possessed a similar affinity at the DAT (16 nM vs. 9 nM of **7a**) and slightly enhanced affinity at the 5-HTT (129 nM vs. 220 nM of **7a**) relative to **7a**. Compound **7e** with an electron-withdrawing trifluoromethyl group also had loss of potency compared to **7a**. We previously found that a combination of 3'-halogen atoms with 4'-substituents on the 3 β -phenyl ring usually led to enhanced affinity at the DAT.²⁵ The addition of a bromo group *ortho* to the 4'-methylthio group of **7a**, however, had almost no effect on binding affinity at the DAT, 5-HTT, and NET. The 4'-methylsulfinyl compounds **7f** and **7g** were less potent than the corresponding 4'-methylthio analogues **7e** and **7a**, respectively, while still having reasonable affinities at all three transporters. The 4'-methylsulfonyl analogue **7h** had much less affinity, in particular for the DAT and NET with IC₅₀ and K_i values >10 μ M, respectively. With the exception of **7c**, all the 4'-alkylthiol and 4'-methylsulfinyl tropanes **7a**, **7b**, and **7d-g** possessed nanomolar or subnanomolar affinity at the 5-HTT (K_i = 0.6-4.5 nM) and good selectivity for the 5-HTT over the NET (NET/5-HTT = 120-314). However, none of these compounds had selectivity similar to **5** for both the DAT and 5-HTT relative to the NET.

The tertiary amino nitrogen of cocaine and its 3-phenyltropane analogues may contribute to the electrostatic or hydrogen-binding interactions between the ligand and transporter binding site.²⁵ Consequently, N-substituents that change electron density at the nitrogen atom should affect their binding properties, possibly with gains in selectivity for specific transporters. In our SAR studies, we noticed that removing the *N*-methyl group from 3 β -phenyltropanes resulted in enhanced affinity for binding at the 5-HTT and NET with virtually no change in binding affinity at the DAT.²⁵ In addition, studies from other groups showed that N-substituted analogues of 3 β -(4-iodophenyl)tropane yielded higher 5-HTT affinity.^{45, 46} Replacement of the *N*-methyl group by hydrogen in 3 β -(4-methylthiophenyl)tropane **7a** to give *N*-nortropane **8a** exhibited approximately 4- and 10-fold increases at the 5-HTT and NET, respectively, but had 3-fold less affinity at the DAT (Table 2). Compound **8a** with an IC₅₀ value of 28 nM at the DAT, and K_i values of 0.19 nM and 21 nM at 5-HTT and NET, respectively, is a potent and nonselective monoamine uptake inhibitor. N-substituents of 3-fluoropropyl, allyl, and propyl groups in **9a**, **10a**, and **11a**, respectively, showed less affinities at all three transporters than the *N*-methyl substituted **7a**, though they still possessed appreciable affinities at the 5-HTT with K_i values ranging from 3 nM to 5.7 nM. The similar affinities of **10a** and **11a** at the DAT and 5-HTT suggest that electronic as well as steric factors of N-substituents may not play an important role in receptor binding of these compounds. An analogous effect was observed upon replacement of the *N*-methyl group in 3 β -(4-ethylthiophenyl)tropane **7b** by hydrogen or alkyl groups to give **8b-11b**, while in this case, they all possessed less affinities than the corresponding 4'-methylthio analogues.

In summary, a new series of 3 β -(4-alkylthio, 4-methylsulfinyl, and 4-methylsulfonylphenyl) tropane and 3 β -(4-alkylthiophenyl)nortropane derivatives were synthesized and evaluated for their monoamine transporter binding affinities. With exception of the 4'-methylsulfonyl

analogue **7h**, all the tested compounds exhibited high binding affinities at the 5-HTT with K_i values ranging from 0.19 nM to 49 nM. The 3 β -(4-methylthiophenyl)nortropine **8a** had a K_i value of 0.19 nM at the 5-HTT and also appreciable affinity at the DAT and NET (IC_{50} = 28 nM and K_i = 21 nM, respectively), and thus is the most potent compound for all three transporters in the series. Compound **7a** and its *N*-(3-fluoropropyl) analogue **9a** and *N*-allyl analogue **10a** are the most selective compounds for the 5-HTT relative to the NET. However, none of the tested compounds showed good selectivity for the DAT over the NET. This study provided useful SAR information for further design of potent and selective monoamine uptake inhibitors.

5. Experimental

Melting points were determined using a MEL-TEMP II capillary melting point apparatus and are uncorrected. Nuclear magnetic resonance (1H NMR and ^{13}C NMR) spectra were obtained on a Bruker Avance DPX-300 MHz NMR spectrometer. Chemical shifts are reported in parts per million (ppm) with reference to internal solvent. Mass spectra (MS) were run on a Perkin-Elmer Sciex API 150 EX mass spectrometer equipped with ESI (turbo spray) source or on a Hewlett Packard 5989A instrument by electron impact. Elemental analyses were performed by Atlantic Microlab Inc., Atlanta, GA. Optical rotations were measured on an AutoPol III polarimeter, purchased from Rudolf Research. Analytical thin-layer chromatography (TLC) was carried out using EMD silica gel 60 F₂₅₄ TLC plates. TLC visualization was achieved with a UV lamp or in an iodine chamber. Flash column chromatography was done on a CombiFlash Companion system using Isco preppacked silica gel columns or using EM Science silica gel 60Å (230–400 mesh). Unless otherwise stated, reagent-grade chemicals were obtained from commercial sources and were used without further purification. All moisture- and air-sensitive reactions and reagent transfers were carried out under dry nitrogen.

5.1. 3 β -(4-Methylthiophenyl)tropane-2 β -carboxylic acid methyl ester (**7a**)

Magnesium (0.72 g, 0.03 mol) was weighed into a 100 mL round bottom flask. A single crystal of iodine was added and the system was flushed with nitrogen and flame dried. After cooling to room temperature, anhydrous Et₂O (2 mL) was added. A solution of 4-bromothiophenol (5.08 g, 0.025 mol) in anhydrous Et₂O (20 mL) was prepared and 2 mL was added. After addition of a catalytic amount of 1,2-dibromoethane, the orange iodine color disappeared which indicated the initiation was successful. The rest of the 4-bromothiophenol solution was added slowly over 30 min while the solution was kept refluxing. After addition, the reaction mixture was refluxed for 1 h. The freshly prepared Grignard solution was then diluted with anhydrous Et₂O (76 mL) and cooled to –45 °C. A solution of anhydroecgonine methyl ester (**12**) (1.80 g, 0.01 mol) in 1:1 mixture of CH₂Cl₂-Et₂O (15 mL) was added slowly and the reaction mixture was stirred at –45 °C for another 2 h. After cooling to –78 °C, the reaction was quenched by slow addition of a solution of TFA (4.60 mL, 60.0 mmol) in Et₂O (6 mL). The mixture was warmed to room temperature and 6 N HCl (40 mL) was added. The aqueous layer was separated, made basic to pH 11 using NH₄OH, and extracted with EtOAc (3 $\times$ 100 mL). The combined EtOAc extracts were washed with brine (3 $\times$ 50 mL), dried (Na₂SO₄), and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0 $\rightarrow$ 20% Et₂O in hexane with the addition of 5% Et₃N afforded **7a** (2.60 g, 87%) as an oil. 1H NMR (300 MHz; CDCl₃) δ 7.18 (s, 4H), 3.60–3.51 (m, 1H), 3.50 (s, 3H), 3.42–3.34 (m, 1H), 2.96 (ddd, J = 12.8, 5.1, 5.1 Hz, 1H), 2.90–2.84 (m, 1H), 2.57 (ddd, J = 12.6, 12.8, 3.0 Hz, 1H), 2.45 (s, 3H), 2.30–2.01 (m, 5H), 1.78–1.54 (m, 3H); ^{13}C NMR (75 MHz; CDCl₃) δ 171.6, 139.9, 135.0, 127.6, 126.3, 65.0, 62.0, 52.4, 50.7, 41.7, 33.8, 33.1, 25.6, 24.9, 15.8; MS (EI) m/z 305 (M⁺). The free base was converted to the hydrochloride salt: mp 157–158 °C; $[\alpha]_D^{20}$ –128° (c 0.29, CH₃OH); Anal. Calcd for C₁₇H₂₃NO₂S·HCl·1.75H₂O: C, 54.68; H, 7.42; N, 3.75. Found: C, 54.79; H, 7.50; N, 3.77.

5.2. 3β-(4-Ethylthiophenyl)tropane-2β-carboxylic acid methyl ester (7b)

The procedure for **7a** was followed using 1.80 g (0.01 mol) of **12** to give 1.98 g (62%) of **7b** as a solid: mp 55–56 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.30–7.17 (m, 4H), 3.63–3.53 (m, 1H), 3.49 (s, 3H), 3.40–3.32 (m, 1H), 3.05–2.85 (m, 4H), 2.57 (ddd, *J* = 12.6, 12.6, 3.0 Hz, 1H), 2.28–2.00 (m, 5H), 1.80–1.55 (m, 3H), 1.28 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 171.6, 140.7, 133.1, 128.7, 127.6, 65.0, 62.0, 52.4, 50.7, 41.7, 33.7, 33.2, 27.6, 25.6, 24.9, 14.2; MS (ESI) *m/z* 320.2 (M+1). The free base was converted to the hydrochloride salt: mp 155–157 °C; [α]_D²⁰ –120° (*c* 0.35, CH₃OH); Anal. Calcd for C₁₈H₂₅NO₄·HCl·1.5H₂O: C, 56.46; H, 7.63; N, 3.66. Found: C, 56.70; H, 7.61; N, 3.65.

5.3. 3β-(4-Isopropylthiophenyl)tropane-2β-carboxylic acid methyl ester (7c)

The procedure for **7a** was followed using 850 mg (4.68 mmol) of **12** to give 0.96 g (61%) of **7c** as a solid: mp 103–105 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.30 (d, *J* = 8.3 Hz, 2H), 7.18 (d, *J* = 8.3 Hz, 2H), 3.62–3.53 (m, 1H), 3.48 (s, 3H), 3.42–3.22 (m, 2H), 2.97 (ddd, *J* = 12.5, 5.1, 5.1 Hz, 1H), 2.92–2.87 (m, 1H), 2.58 (ddd, *J* = 12.5, 12.6, 2.4 Hz, 1H), 2.30–2.04 (m, 5H), 1.78–1.54 (m, 3H), 1.26 (d, *J* = 6.0 Hz, 6H); ¹³C NMR (75 MHz; CDCl₃) δ 172.2, 142.2, 132.5, 132.2, 128.0, 65.5, 62.5, 53.0, 51.3, 42.1, 38.6, 34.2, 33.7, 26.1, 25.3, 23.4; MS (ESI) *m/z* 334.4 (M+1). The free base was converted to the hydrochloride salt: mp 165–166 °C; [α]_D²⁰ –116° (*c* 0.38, CH₃OH); Anal. Calcd for C₁₉H₂₇NO₂·HCl·0.75H₂O: C, 59.51; H, 7.75; N, 3.65. Found: C, 59.62; H, 7.89; N, 3.37.

5.4. 3β-(4-Trifluoromethylthiophenyl)tropane-2β-carboxylic acid methyl ester (7d)

The procedure for **7a** was followed using 900 mg (5.00 mmol) of **12** to give 0.12 g (7%) of **7d** as a solid: mp 64–65 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.60–7.51 (m, 2H), 7.37–6.27 (m, 2H), 3.65–3.55 (m, 1H), 3.49 (s, 3H), 3.41–3.32 (m, 1H), 3.02 (ddd, *J* = 12.5, 5.1, 5.1 Hz, 1H), 2.97–2.88 (m, 1H), 2.56 (ddd, *J* = 12.6, 12.5, 2.7 Hz, 1H), 2.33–2.05 (m, 5H), 1.80–1.54 (m, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 172.0, 146.9, 136.1, 129.9 (q, *J*_{C,F} = 306 Hz), 128.7, 121.4 (q, *J*_{C,F} = 1.9 Hz), 65.5, 62.3, 52.8, 51.3, 42.1, 34.0, 33.9, 26.0, 25.4; MS (EI) *m/z* 359 (M⁺). The free base was converted to the hydrochloride salt: mp 169–171 °C; [α]_D²⁰ –113° (*c* 0.35, CH₃OH); Anal. Calcd for C₁₇H₂₀F₃NO₂·HCl·0.25H₂O: C, 51.00; H, 5.41; N, 3.50. Found: C, 50.87; H, 5.52; N, 3.37.

5.5. 3β-(3-Bromo-4-methylthiophenyl)tropane-2β-carboxylic acid methyl ester (7e), 3β-(3-bromo-4-methylsulfinylphenyl)tropane-2β-carboxylic acid methyl ester (7f), and 3β-(4-methylsulfinylphenyl)tropane-2β-carboxylic acid methyl ester (7g)

To a stirred solution of **7a** (153 mg, 0.50 mmol) in AcOH (2 mL) at room temperature under nitrogen was added Br₂ (0.056 mL, 1.00 mmol). After stirring for 1 h, the reaction mixture was poured into a mixture of NaHCO₃ and ice. The resultant solution was extracted with CH₂Cl₂ (3 × 30 mL). The combined CH₂Cl₂ extracts were washed with 20% Na₂S₂O₃ (30 mL), brine (30 mL), dried (Na₂SO₄), and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0 → 5% Et₂O in hexane with the addition of 5% Et₃N followed by 0 → 30% CH₃OH in CH₂Cl₂ with the addition of 1% NH₄OH afforded **7e** (25.0 mg, 13%), **7f** (30.0 mg, 15%), and **7g** (55.0 mg, 34%).

Compound **7e**: oil; ¹H NMR (300 MHz; CDCl₃) δ 7.39 (d, *J* = 1.5 Hz, 1H), 7.23 (dd, *J* = 8.1, 1.5 Hz, 1H), 7.05 (d, *J* = 8.1 Hz, 1H), 3.64–3.54 (m, 1H), 3.53 (s, 3H), 3.42–3.33 (m, 1H), 2.94 (ddd, *J* = 12.4, 4.8, 4.8 Hz, 1H), 2.88–2.81 (m, 1H), 2.53 (ddd, *J* = 12.4, 12.3, 2.7 Hz, 1H), 2.44 (s, 3H), 2.30–2.02 (m, 5H), 1.80–1.57 (m, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 172.1, 141.7, 136.6, 132.0, 127.1, 125.6, 121.8, 65.5, 62.4, 52.8, 51.4, 42.1, 34.2, 33.4, 26.1, 25.4, 16.1; MS (ESI) *m/z* 384.3 (M+1) (⁷⁹Br), 386.2 (M+1) (⁸¹Br). The free base was converted to

the hydrochloride salt: mp 148–150 °C; $[\alpha]_D^{20}$ -90° (*c* 0.30, CH₃OH); Anal. Calcd for C₁₇H₂₂BrNO₂S·HCl·0.5H₂O: C, 47.51; H, 5.63; N, 3.26. Found: C, 47.64; H, 5.99; N, 3.00.

Compound **7f**: solid; mp 63–66 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.82 (dd, *J* = 8.7, 2.4 Hz, 1H), 7.50–7.40 (m, 2H), 3.68–3.58 (m, 1H), 3.54 (s, 3H), 3.47–3.37 (m, 1H), 3.10–2.90 (m, 2H), 2.79 (s, 3H), 2.68–2.52 (m, 1H), 2.32–2.03 (m, 5H), 1.80–1.55 (m, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 171.8, 148.8, 142.4, 132.0, 127.7, 125.2, 118.2, 65.3, 62.2, 52.5, 51.4, 42.1, 41.9, 33.9, 33.7, 25.8, 25.2; MS (ESI) *m/z* 400.3 (M+1) (⁷⁹Br), 402.2 (M+1) (⁸¹Br). The free base was converted to the hydrochloride salt: mp 148–150 °C; $[\alpha]_D^{20}$ -91° (*c* 0.28, CH₃OH); Anal. Calcd for C₁₇H₂₂BrNO₃S·HCl·1.5H₂O: C, 44.02; H, 5.65; N, 3.02. Found: C, 43.75; H, 5.65; N, 2.99.

Compound **7g**: solid; mp 94–97 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.55 (d, *J* = 7.6 Hz, 2H), 7.42 (d, *J* = 7.6 Hz, 2H), 3.70–3.60 (m, 1H), 3.50 (s, 3H), 3.47–3.37 (m, 1H), 3.10–3.02 (m, 1H), 2.98–2.90 (m, 1H), 2.70 (s, 3H), 2.69–2.52 (m, 1H), 2.32–2.05 (m, 5H), 1.86–1.60 (m, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 171.8, 146.7, 142.7, 128.4, 123.2, 65.2, 62.1, 52.5, 51.2, 43.8, 41.9, 33.8, 25.8, 25.1; MS (ESI) *m/z* 322.3 (M+1). The free base was converted to the hydrochloride salt: mp 115 °C (fusion); $[\alpha]_D^{20}$ -115° (*c* 0.31, CH₃OH); Anal. Calcd for C₁₇H₂₃NO₃S·HCl·1.5H₂O: C, 53.05; H, 7.07; N, 3.64. Found: C, 53.30; H, 7.01; N, 3.78.

3β-(4-Methylsulfonylphenyl)tropane-2β-carboxylic acid methyl ester (7h)—To a stirred solution of **7a** (500 mg, 1.60 mmol) in AcOH (13 mL) at room temperature was added 30% H₂O₂ (4.66 mL). After stirring at room temperature for 20 h, the reaction mixture was poured into a mixture of NaHCO₃ and Na₂SO₃ in water, and extracted with EtOAc (3 × 50 mL). The combined EtOAc extracts were washed with brine (3 × 50 mL) and dried (Na₂SO₄). Removal of the solvent under reduced pressure afforded **7h** (470 mg, 84%) as a solid: mp 123–124 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.89–7.80 (m, 2H), 7.50–7.42 (m, 2H), 3.67–3.58 (m, 1H), 3.52 (s, 3H), 3.43–3.34 (m, 1H), 3.02–2.92 (m, 5H), 2.61 (ddd, *J* = 12.3, 12.3, 2.7 Hz, 1H), 2.30–2.07 (m, 5H), 1.80–1.56 (m, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 171.6, 150.1, 137.7, 128.1, 126.8, 65.2, 62.0, 52.4, 51.1, 44.4, 41.8, 33.8, 33.6, 25.6, 25.1; MS (EI) *m/z* 337 (M⁺). The free base was converted to the hydrochloride salt: mp 159–162 °C; $[\alpha]_D^{20}$ -106° (*c* 0.74, CH₃OH); Anal. Calcd for C₁₇H₂₃NO₄S·HCl·1.25H₂O: C, 51.51; H, 6.74; N, 3.53. Found: C, 51.65; H, 6.58; N, 3.42.

3β-(4-Methylthiophenyl)nortropane-2β-carboxylic acid methyl ester (8a)—A mixture of **7a** (310 mg, 1.00 mmol) and 1-chloroethyl chloroformate (0.43 mL, 4.00 mmol) in 1,2-dichloroethane (3 mL) was refluxed under nitrogen for 20 h. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in MeOH (10 mL). After refluxing for 5 h, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was made basic using NaHCO₃ and extracted with CH₂Cl₂ (3 × 50 mL). The combined CH₂Cl₂ extracts were dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0 → 5% CH₃OH in CH₂Cl₂ with the addition of 1% NH₄OH afforded **8a** (250 mg, 86%) as a solid: mp 48–49 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.25–7.09 (m, 4H), 3.78–3.68 (m, 2H), 3.38 (s, 3H), 3.20 (ddd, *J* = 12.3, 5.4, 5.4 Hz, 1H), 2.73 (s, 2H), 2.52–2.33 (m, 4H), 2.20–1.97 (m, 2H), 1.85–1.55 (m, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 173.8, 139.4, 136.2, 127.9, 126.7, 56.4, 53.7, 51.2, 35.3, 33.8, 29.1, 27.7, 16.0; MS (ESI) *m/z* 292.1 (M+1). The free base was converted to the tartrate salt: mp 118–121 °C; $[\alpha]_D^{20}$ -103° (*c* 0.26, CH₃OH); Anal. Calcd for C₂₀H₂₇NO₈S: C, 54.41; H, 6.16; N, 3.17. Found: C, 54.27; H, 6.15; N, 3.09.

3β-(4-Ethylthiophenyl)nortropane-2β-carboxylic acid methyl ester (8b)—The procedure for **8a** was followed using 640 mg (2.00 mmol) of **7b** to give 530 mg (87%) of **8b** as a solid: mp 49–51 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.24 (d, *J* = 8.4 Hz, 2H), 7.10 (d, *J* =

8.4 Hz, 2H), 3.80–3.68 (m, 2H), 3.37 (s, 3H), 3.34–3.15 (m, 2H), 2.90 (q, $J = 7.3$ Hz, 2H), 2.80–2.70 (m, 1H), 2.40 (ddd, $J = 12.9, 12.9, 2.4$ Hz, 1H), 2.25–1.94 (m, 2H), 1.87–1.56 (m, 3H), 1.27 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (75 MHz; CDCl_3) δ 173.7, 140.0, 134.4, 129.2, 127.8, 56.3, 53.7, 51.1, 51.0, 35.2, 33.6, 29.0, 27.8, 27.6, 14.3; MS (ESI) m/z 306.1 ($M+1$). The free base was converted to the tartrate salt: mp 108–110 °C; $[\alpha]_{\text{D}}^{20} -79^\circ$ (c 0.21, CH_3OH); Anal. Calcd for $\text{C}_{21}\text{H}_{29}\text{NO}_8\text{S} \cdot 0.25\text{H}_2\text{O}$: C, 54.83; H, 6.46; N, 3.04. Found: C, 54.69; H, 6.45; N, 3.02.

3 β -(4-Methylthiophenyl)-8-(3-fluoropropyl)nortropane-2 β -carboxylic acid methyl ester (9a)

—To a stirred mixture of **8a** (146 mg, 0.50 mmol) and K_2CO_3 (138 mg, 1.00 mmol) in CH_3CN (5 mL) at room temperature under nitrogen was added 1-bromo-3-fluoro-propane (93.0 mg, 0.60 mmol). After refluxing for 2 h, the reaction mixture was cooled to room temperature and diluted with EtOAc (50 mL). The mixture was washed with brine (3×30 mL), dried (Na_2SO_4), and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0 $\rightarrow$ 5% Et_2O in hexane with the addition of 5% Et_3N afforded **9a** (165 mg, 94%) as an oil: ^1H NMR (300 MHz; CDCl_3) δ 7.18 (s, 4H), 4.60 (t, $J = 6.0$ Hz, 1H), 4.44 (t, $J = 6.0$ Hz, 1H), 3.71–3.64 (m, 1H), 3.49 (s, 3H), 3.43–3.37 (m, 1H), 2.98 (ddd, $J = 12.6, 4.8, 4.8$ Hz, 1H), 2.93–2.87 (m, 1H), 2.56 (ddd, $J = 12.6, 12.6, 2.7$ Hz, 1H), 2.45 (s, 3H), 2.43–2.30 (m, 2H), 2.18–1.92 (m, 2H), 1.86–1.58 (m, 5H); ^{13}C NMR (75 MHz; CDCl_3) δ 172.0, 140.5, 135.3, 128.0, 126.7, 82.4 (d, $J_{\text{C,F}} = 162$ Hz), 63.4, 61.6, 52.9, 51.0, 49.4 ($J_{\text{C,F}} = 5.7$ Hz), 34.1 (d, $J_{\text{C,F}} = 18.5$ Hz), 30.4, 30.1, 26.2, 26.1, 16.3; MS (ESI) m/z 352.6 ($M+1$). The free base was converted to the hydrochloride salt: mp 85–87 °C; $[\alpha]_{\text{D}}^{20} -120^\circ$ (c 0.53, CH_3OH); Anal. Calcd for $\text{C}_{19}\text{H}_{26}\text{FNO}_2\text{S} \cdot \text{HCl} \cdot 1.5 \text{H}_2\text{O}$: C, 54.99; H, 7.29; N, 3.38. Found: C, 55.09; H, 7.14; N, 3.43.

3 β -(4-Ethylthiophenyl)-8-(3-fluoropropyl)nortropane-2 β -carboxylic acid methyl ester (9b)

—The procedure for **9a** was followed using 100 mg (0.33 mmol) of **8b** to give 105 mg (87%) of **9b** as an oil: ^1H NMR (300 MHz; CDCl_3) δ 7.26–7.14 (m, 4H), 4.60 (t, $J = 6.0$ Hz, 1H), 4.44 (t, $J = 6.0$ Hz, 1H), 3.71–3.63 (m, 1H), 3.48 (s, 3H), 3.43–3.38 (m, 1H), 3.02–2.85 (m, 4H), 2.57 (ddd, $J = 12.6, 12.6, 2.7$ Hz, 1H), 2.44–2.31 (m, 2H), 2.26–1.92 (m, 2H), 1.86–1.57 (m, 5H), 1.28 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (75 MHz; CDCl_3) δ 172.0, 141.3, 133.5, 129.3, 128.1, 82.4 (d, $J_{\text{C,F}} = 162$ Hz), 63.4, 61.6, 53.0, 51.0, 49.4 (d, $J_{\text{C,F}} = 5.7$ Hz), 34.1 (d, $J_{\text{C,F}} = 14.6$ Hz), 30.4, 30.1, 28.2, 26.2, 26.1, 14.6; MS (ESI) m/z 366.5 ($M+1$); The free base was converted to the hydrochloride salt: mp 165–167 °C; $[\alpha]_{\text{D}}^{20} -118^\circ$ (c 0.28, CH_3OH); Anal. Calcd for $\text{C}_{20}\text{H}_{28}\text{FNO}_2\text{S} \cdot \text{HCl}$: C, 59.76; H, 7.27; N, 3.48. Found: C, 59.76; H, 7.23; N, 3.26.

3 β -(4-Methylthiophenyl)-8-allylnortropane-2 β -carboxylic acid methyl ester (10a)

—To a stirred mixture of **8a** (582 mg, 2.00 mmol), K_2CO_3 (552 mg, 4.00 mmol), and KI (10.0 mg) in CH_3CN (10 mL) at room temperature under nitrogen was added allyl bromide (0.21 mL, 2.40 mmol). After stirring at room temperature for 3 h, the reaction mixture was diluted with EtOAc (50 mL). The mixture was washed with brine (3×30 mL), dried (Na_2SO_4), and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0 $\rightarrow$ 5% Et_2O in hexane with the addition of 5% Et_3N afforded **10a** (520 mg, 79%) as a solid: mp 46–48 °C; ^1H NMR (300 MHz; CDCl_3) δ 7.21–7.15 (m, 4H), 5.86–5.68 (m, 1H), 5.18–4.94 (m, 2H), 3.71–3.64 (m, 1H), 3.49 (s, 3H), 3.47–3.41 (m, 1H), 3.08–2.96 (m, 2H), 2.92–2.78 (m, 2H), 2.60 (ddd, $J = 12.6, 12.6, 2.7$ Hz, 1H), 2.45 (s, 3H), 2.18–1.97 (m, 2H), 1.82–1.58 (m, 3H); ^{13}C NMR (75 MHz; CDCl_3) δ 171.8, 140.2, 136.6, 135.2, 127.9, 126.5, 116.2, 61.9, 61.1, 56.6, 52.7, 50.8, 34.0, 33.8, 26.0, 25.8, 16.0; MS (ESI) m/z 332.5 ($M+1$). The free base was converted to the hydrochloride salt: mp 82–84 °C; $[\alpha]_{\text{D}}^{20} -78^\circ$ (c 0.29, CH_3OH); Anal. Calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_2\text{S} \cdot \text{HCl} \cdot 0.5\text{H}_2\text{O}$: C, 60.54; H, 7.22; N, 3.72. Found: C, 60.36; H, 7.32; N, 3.44.

3β-(4-Ethylthiophenyl)-8-allylnortropane-2β-carboxylic acid methyl ester (10b)

—The procedure for **10a** was followed using 270 mg (0.89 mmol) of **8b** to give 255 mg (83%) of **10b** as a solid: mp 71–72 °C; ¹H NMR (300 MHz; CDCl₃) δ 7.29–7.14 (m, 4H), 5.85–5.68 (m, 1H), 5.18–4.95 (m, 2H), 3.73–3.66 (m, 1H), 3.49 (s, 3H), 3.46–3.40 (m, 1H), 3.08–2.78 (m, 6H), 2.60 (ddd, *J* = 12.6, 12.6, 2.7 Hz, 1H), 2.19–2.04 (m, 2H), 1.80–1.55 (m, 3H), 1.28 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 171.9, 141.1, 136.7, 133.4, 129.1, 128.0, 116.3, 62.1, 61.2, 56.7, 52.8, 51.0, 34.1, 34.0, 28.0, 26.1, 25.9, 14.5; MS (ESI) *m/z* 346.3 (*M* + 1). The free base was converted to the hydrochloride salt: mp 71–73 °C; [α]_D²⁰ –72° (*c* 0.29, CH₃OH); Anal. Calcd for C₂₀H₂₇NO₂S·HCl·0.25H₂O: C, 62.16; H, 7.43; N, 3.62. Found: C, 62.28; H, 7.65; N, 3.49.

3β-(4-Methylthiophenyl)-8-propylnortropane-2β-carboxylic acid methyl ester (11a)

—A mixture of **10a** (130 mg, 0.40 mmol) and 10 wt% Pd/C (26.0 mg) in EtOH was hydrogenated at 1 atm for 16 h. The mixture was filtered through a short pad of Celite and the filtrate was concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel using 0 → 10% Et₂O in hexane with the addition of 3% Et₃N afforded **11a** (115 mg, 88%) as an oil: ¹H NMR (300 MHz; CDCl₃) δ 7.21–7.15 (m, 4H), 3.76–3.66 (m, 1H), 3.49 (s, 3H), 3.43–3.34 (m, 1H), 2.97 (ddd, *J* = 12.5, 5.1, 5.1 Hz, 1H), 2.93–2.87 (m, 1H), 2.57 (ddd, *J* = 12.5, 12.3, 2.7 Hz, 1H), 2.44 (s, 3H), 2.28–1.94 (m, 4H), 1.80–1.58 (m, 3H), 1.50–1.30 (m, 2H), 0.87 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 172.2, 140.7, 135.3, 128.1, 126.8, 62.8, 62.0, 55.8, 53.0, 51.1, 34.3, 34.1, 26.3, 26.0, 22.4, 16.3, 11.9; MS (ESI) *m/z* 334.3 (*M* + 1). The free base was converted to the hydrochloride salt: mp 83–85 °C; [α]_D²⁰ –115° (*c* 0.34, CH₃OH); Anal. Calcd for C₁₉H₂₇NO₂S·HCl·0.75H₂O: C, 59.51; H, 7.75; N, 3.65. Found: C, 59.78; H, 8.03; N, 3.27.

3β-(4-Ethylthiophenyl)-8-propylnortropane-2β-carboxylic acid methyl ester (11b)

—The procedure for **11a** was followed using 140 mg (0.41 mmol) of **10b** to give 85.0 mg (60%) of **11b** as an oil: ¹H NMR (300 MHz; CDCl₃) δ 7.25–7.05 (m, 4H), 3.68–3.55 (m, 1H), 3.41 (s, 3H), 3.34–3.23 (m, 1H), 2.94–2.75 (m, 4H), 2.50 (ddd, *J* = 12.5, 12.5, 2.7 Hz, 1H), 2.22–1.82 (m, 4H), 1.70–1.43 (m, 3H), 1.42–1.20 (m, 2H), 1.20 (t, *J* = 7.4 Hz, 3H), 0.79 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 172.1, 141.5, 133.4, 129.3, 128.1, 62.8, 61.9, 55.8, 53.0, 51.0, 34.3, 34.1, 28.2, 26.3, 26.0, 22.4, 14.6, 11.9; MS (ESI) *m/z* 348.0 (*M* + 1). The free base was converted to the hydrochloride salt: mp 78–80 °C; [α]_D²⁰ –124° (*c* 0.39, CH₃OH); Anal. Calcd for C₂₀H₂₉NO₂S·HCl·1.25H₂O: C, 59.09; H, 8.06; N, 3.45. Found: C, 59.11; H, 8.15; N, 3.49.

Acknowledgements

This research was supported by the National Institute on Drug Abuse, Grant No. DA05477.

References

1. Reith MEA, Meisler BE, Serphen H, Lajtha A. *Biochem. Pharmacol* 1986;35:1123–1129. [PubMed: 3964292]
2. Riddle EL, Fleckenstein AE, Hanson GR. *The AAPS Journal* 2005;7:E847–E851. [PubMed: 16594636]
3. Heikkilä RE, Manzino L. *Eur. J. Pharmacol* 1984;103:241–248. [PubMed: 6237922]
4. Zhu J, Reith MEA. *CNS Neurol. Disord. Drug Targets* 2008;7:393–409. [PubMed: 19128199]
5. Xi ZX, Gardner EL. *Curr. Drug Abuse Rev* 2008;1:303–327. [PubMed: 19430578]
6. Carroll FI, Lewin AH, Boja JW, Kuhar MJ. *J. Med. Chem* 1992;35:969–981. [PubMed: 1552510]
7. Kuhar MJ, Ritz MC, Boja JW. *Trends Neurosci* 1991;14:299–302. [PubMed: 1719677]
8. Kalivas PW. *Am. J. Addict* 2007;16:71–78. [PubMed: 17453607]

9. Howell LL, Kimmel HL. *Biochem. Pharmacol* 2008;75:196–217. [PubMed: 17825265]
10. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, Caron MG. *Nat. Neurosci* 1998;1:132–137. [PubMed: 10195128]
11. Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL. *Psychopharmacology (Berl)* 2000;153:139–147. [PubMed: 11255924]
12. Wise RA, Leeb K, Pocock D, Newton P, Burnette B, Justice JB. *Psychopharmacology (Berl)* 1995;120:10–20. [PubMed: 7480530]
13. Volkow ND, Wang G-J, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE. *Nature* 1997;386:827–833. [PubMed: 9126740]
14. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. *Science* 1987;237:1219–1223. [PubMed: 2820058]
15. Bergman J, Madras BK, Johnson SE, Spealman RD. *J. Pharmacol. Exp. Ther* 1989;251:150–155. [PubMed: 2529365]
16. Carroll FI, Howell LL, Kuhar MJ. *J. Med. Chem* 1999;42:2721–2736. [PubMed: 10425082]
17. Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL. *J. Pharmacol. Exp. Ther* 2007;320:757–765. [PubMed: 17105829]
18. Ritz MC, Kuhar MJ. *J. Pharmacol. Exp. Ther* 1989;248:1010–1017. [PubMed: 2703961]
19. Howell LL, Byrd LD. *J. Pharmacol. Exp. Ther* 1995;275:1551–1559. [PubMed: 8531128]
20. Spealman RD. *Psychopharmacology (Berl)* 1993;112:93–99. [PubMed: 7871015]
21. Blough, Bruce E.; Abraham, P.; Lewin, Anita H.; Kuhar, Michael J.; Boja, John W.; Carroll, FI. *J. Med. Chem* 1996;39:4027–4035. [PubMed: 8831768]
22. Blough BE, Abraham P, Mills AC, Lewin AH, Boja JW, Scheffel U, Kuhar MJ, Carroll FI. *J. Med. Chem* 1997;40:3861–3864. [PubMed: 9397165]
23. Jin C, Navarro HA, Carroll FI. *J. Med. Chem* 2008;51:8048–8056. [PubMed: 19053748]
24. Carey RJ, Huston JP, Müller CP. *Prog. Brain Res* 2008;172:347–360. [PubMed: 18772041]
25. Carroll FI. *J. Med. Chem* 2003;46:1775–1794. [PubMed: 12723940]
26. Davies HML, Saikali E, Huby NJS, Gilliat VJ, Matasi JJ, Sexton T, Childers SR. *J. Med. Chem* 1994;37:1262–1268. [PubMed: 8176704]
27. Xu L, Kelkar SV, Lomenzo SA, Izenwasser S, Katz JL, Kline RH, Trudell ML. *J. Med. Chem* 1997;40:858–863. [PubMed: 9083474]
28. Carroll, FI.; Lewin, AH.; Mascarella, SW. *Neurotransmitter Transporters: Structure, Function, and Regulation*. Vol. 2nd Edition. Reith, MEA., editor. Humana Press; Totowa, NJ: 2001. p. 381-432.
29. Xu L, Kulkarni SS, Izenwasser S, Katz JL, Kopajtic T, Lomenzo SA, Newman AH, Trudell ML. *J Med Chem* 2004;47:1676–1682. [PubMed: 15027858]
30. Runyon SP, Carroll FI. *Curr. Top. Med. Chem* 2006;6:1825–1843. [PubMed: 17017960]
31. Runyon, SP.; Carroll, FI. *Dopamine Transporters, Chemistry, Biology and Pharmacology*. Trudell, ML.; Izenwasser, S., editors. Wiley; 2007.
32. Kozikowski AP, Araldi GL, Prakash KR, Zhang M, Johnson KM. *J. Med. Chem* 1998;41:4973–4982. [PubMed: 9836615]
33. Jin C, Navarro HA, Carroll FI. *Bioorg. Med. Chem* 2008;16:5529–5535. [PubMed: 18434164]
34. Jin C, Navarro HA, Page K, Carroll FI. *Bioorg. Med. Chem* 2008;16:6682–6688. [PubMed: 18556210]
35. Carroll FI, Pawlusch N, Kuhar MJ, Pollard GT, Howard JL. *J. Med. Chem* 2004;47:296–302. [PubMed: 14711303]
36. Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ. *AAPS J* 2006;8:E196–E203. [PubMed: 16584128]
37. Carroll FI, Fox BS, Kuhar MJ, Howard JL, Pollard GT, Schenk S. *Eur. J. Pharmacol* 2006;553:149–156. [PubMed: 17067572]
38. Carroll FI, Mascarella SW, Kuzemko MA, Gao Y, Abraham P, Lewin AH, Boja JW, Kuhar MJ. *J. Med. Chem* 1994;37:2865–2873. [PubMed: 8071935]
39. Boja JW, Kuhar MJ, Kopajtic T, Yang E, Abraham P, Lewin AH, Carroll FI. *J. Med. Chem* 1994;37:1220–1223. [PubMed: 8164265]

40. Carroll FI, Abraham P, Lewin AH, Parham KA, Boja JW, Kuhar MJ. J. Med. Chem 1992;35:2497–2500. [PubMed: 1619622]
41. Carroll FI, Gao Y, Abraham P, Lewin AH, Lew R, Patel A, Boja JW, Kuhar MJ. J. Med. Chem 1992;35:1813–1817. [PubMed: 1588560]
42. Carroll FI, Gao Y, Rahman MA, Abraham P, Parham K, Lewin AH, Boja JW, Kuhar MJ. J. Med. Chem 1991;34:2719–2925. [PubMed: 1895292]
43. Singh S. Chem. Rev 2000;100:925–1024. [PubMed: 11749256]
44. Carroll FI, Blough BE, Nie Z, Kuhar MJ, Howell LL, Navarro HA. J. Med. Chem 2005;48:2767–2771. [PubMed: 15828814]
45. Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, Baldessarini RJ. J. Med. Chem 1996;39:543–548. [PubMed: 8558525]
46. Tamagnan G, Neumeyer JL, Gao Y, Wang S, Kula NS, Baldessarini RJ. Bioorg. Med. Chem. Lett 1997;7:337–340.

Figure 1.
Structures of cocaine (**1**) and 3β-phenyltropanes

Figure 2.

Structures of 3β-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3β-(4-alkylthiophenyl)nortropene derivatives

Scheme 1.

Reagents and conditions: (a) Grignard reagent, $-45\text{ }^\circ\text{C}$, 2 h, then $-78\text{ }^\circ\text{C}$, TFA.

Scheme 2.

Reagents and conditions: (a) Br_2 , AcOH , 0°C ; (b) 30% H_2O_2 , AcOH , room temperature.

Scheme 3.

Reagents and conditions: (a) 1-chloroethyl chloroformate, 1,2-dichloroethane, reflux; (b) CH₃OH, reflux; (c) 1-bromo-3-fluoropropane, K₂CO₃, CH₃CN, reflux; (d) allyl bromide, KI, K₂CO₃, CH₃CN, room temperature; (e) 10% Pd/C, H₂, EtOH.

Monoamine transporter binding 3β-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane derivatives

Table 1

Compd ^a	R	X	n	DAT, IC ₅₀ ^b (nM) [³ H]WIN35,428	5-HTT, K _i ^b (nM) [³ H]paroxetine	NET, K _i ^b (nM) [³ H]nisoxetine	NET/DAT Ratio	NET/5-HTT Ratio

Cocaine ^c				89.1	95	1990	22	21
5 ^c				6.5 ± 1.3	4.3 ± 0.5	1110 ± 64	171	258
7a	CH ₃	H	0	9 ± 3	0.7 ± 0.2	220 ± 10	24	314
7b	C ₂ H ₅	H	0	232 ± 34	4.5 ± 0.5	1170 ± 300	5	260
7c	CH(CH ₃) ₂	H	0	16 ± 2	23 ± 2	129 ± 2	8	7
7d	CF ₃	H	0	200 ± 70	8 ± 2	1900 ± 300	10	238
7e	CH ₃	Br	0	10.1 ± 1	0.6 ± 0.2	121 ± 12	12	202
7f	CH ₃	Br	1	76 ± 18	3.2 ± 0.4	690 ± 80	9	216
7g	CH ₃	H	1	91 ± 16	4.3 ± 0.6	515 ± 60	6	120
7h	CH ₃	H	2	>10000	208 ± 45	>10000	1	48

^a All compounds were tested as the HCl salt.

^b All values are means ± standard error of three or four experiments performed in triplicate.

^c Data taken from Ref. 23.

Table 2
Monoamine transporter binding properties of 3β-(4-alkylthiophenyl)nortropine derivatives

Compd ^a	R ₁	R ₂	DAT, IC ₅₀ ^c (nM) [³ H]WIN35,428	5-HTT, K _i ^c (nM) [³ H]paroxetine	NET, K _i ^c (nM) [³ H]nisoxetine	NET/DAT Ratio	NET/5-HTT Ratio
7a	CH ₃	CH ₃	9 ± 3	0.7 ± 0.2	220 ± 10	24	314
8a ^b	CH ₃	H	28 ± 6	0.19 ± 0.01	21 ± 6	0.8	110
9a	CH ₃	FCH ₂ CH ₂ CH ₂	112 ± 2	3 ± 1	960 ± 100	9	320
10a	CH ₃	CH ₂ =CHCH ₂	71 ± 25	5.5 ± 0.8	2000 ± 500	28	364
11a	CH ₃	CH ₃ CH ₂ CH ₂	74 ± 20	5.7 ± 0.6	1200 ± 140	16	211
7b	C ₂ H ₅	CH ₃	232 ± 34	4.5 ± 0.5	1170 ± 300	5	260
8b ^b	C ₂ H ₅	H	177 ± 62	1.26 ± 0.05	118 ± 13	0.7	94
9b	C ₂ H ₅	FCH ₂ CH ₂ CH ₂	1200 ± 200	27 ± 2	>2000	2	74
10b	C ₂ H ₅	CH ₂ =CHCH ₂	1100 ± 100	47 ± 3	>2000	2	43
11b	C ₂ H ₅	CH ₃ CH ₂ CH ₂	900 ± 300	49 ± 6	>2000	2	41

^aCompounds were tested as the HCl salt.

^bCompounds were tested as the tartrate salt.

^cAll values are means ± standard error of three or four experiments performed in triplicate.